CLINICAL TRIALS AND OBSERVATIONS Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan- prednisone (VMP) in untreated multiple myeloma patients with renal impairment
نویسندگان
چکیده
Fortunato Morabito,1 Massimo Gentile,1 Carla Mazzone,1 Davide Rossi,2 Francesco Di Raimondo,3 Sara Bringhen,4 Roberto Ria,5 Massimo Offidani,6 Francesca Patriarca,7 Chiara Nozzoli,8 Maria Teresa Petrucci,9 Giulia Benevolo,10 Iolanda Vincelli,11 Tommasina Guglielmelli,12 Mariella Grasso,13 Roberto Marasca,14 Luca Baldini,15 Vittorio Montefusco,16 Pellegrino Musto,17 Nicola Cascavilla,18 Ignazio Majolino,19 Caterina Musolino,20 Michele Cavo,21 Mario Boccadoro,4 and Antonio Palumbo4
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
1Divisione di Ematologia dell’Università di Torino, Azienda Ospedaliera (AO) S. Giovanni Battista, Turin, Italy; 2Ematologia, Azienda Ospedaliera San Giovanni Battista, Turin, Italy; 3Divisione di Ematologia, Ospedale Centrale, Bolzano, Italy; 4Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy; 5Divisione di Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera Cervello, ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
1Centre René Gauducheau, Nantes/St Herblain, France; 2Universita di Torino, Torino, Italy; 3Dana-Farber Cancer Institute, Boston, MA; 4Praxisklinik Dr Schlag, Würzburg, Germany; 5University of Athens, School of Medicine, Athens, Greece; 6Rabin Medical Center, Petah-Tiqva, Israel; 7University of Münster, Münster, Germany; 8Belgian Myeloma Study Group, Brussels, Belgium; 9Institute of Hematology ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
This prospective study evaluated the risk of arterial thrombosis in 195 consecutive patients aged 18 to 65 years with newly diagnosed multiple myeloma (MM). All patients were treated with 3 cycles of VAD (vincristine, doxorubicin, and dexamethasone) or TAD (thalidomide-AD) or PAD (bortezomib-AD) in national trials, followed by high-dose melphalan and autologous stem cell transplantation. For a ...
متن کاملBrief Report CLINICAL TRIALS AND OBSERVATIONS A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
In amyloid light chain (AL) amyloidosis, clonal plasma cells use proteasomes to cope with misfolded light chain-induced proteotoxicity, and theproteasome inhibitor bortezomib is a potential targeted therapy. Early reports supported this expectation, showing high response rates, particularly upfront. A prospective trial showed that single-agent bortezomib ishighlyand rapidlyeffective.Combination...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Anders Waage,1 Peter Gimsing,2 Peter Fayers,1,3 Niels Abildgaard,4 Lucia Ahlberg,5 Bo Björkstrand,6 Kristina Carlson,7 Inger Marie Dahl,8 Karin Forsberg,9 Nina Gulbrandsen,10 Einar Haukås,11 Øyvind Hjertner,1 Martin Hjorth,12 Torbjörn Karlsson,13 Lene Meldgaard Knudsen,14 Johan Lanng Nielsen,15 Olle Linder,16 Ulf-Henrik Mellqvist,17 Ingerid Nesthus,18 Jürgen Rolke,19 Maria Strandberg,20 Jon Hja...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2011